Skip to main content

ADVERTISEMENT

immuno-oncology

News
07/01/2020
The Association of Community Cancer Centers (ACCC) Immuno-Oncology Institute released an assessment of the current state of immuno-oncology that highlights for cancer care professionals the current research,...
The Association of Community Cancer Centers (ACCC) Immuno-Oncology Institute released an assessment of the current state of immuno-oncology that highlights for cancer care professionals the current research,...
The...
07/01/2020
Journal of Clinical Pathways
News
06/09/2020
Real-world patients with metastatic non-small cell lung cancer (NSCLC) who receive first-line immunotherapy are less likely to incur adverse event-related costs than those treated with first-line cytotoxic...
Real-world patients with metastatic non-small cell lung cancer (NSCLC) who receive first-line immunotherapy are less likely to incur adverse event-related costs than those treated with first-line cytotoxic...
...
06/09/2020
Journal of Clinical Pathways
Department
09/28/2016
JCP Editors
Data from the Paris-based Molecular Screening for Cancer Treatment Optimization (MOSCATO) trial demonstrates that establishing molecular portraits improves survival for patients with advanced cancer by tailoring...
Data from the Paris-based Molecular Screening for Cancer Treatment Optimization (MOSCATO) trial demonstrates that establishing molecular portraits improves survival for patients with advanced cancer by tailoring...
Data...
09/28/2016
Journal of Clinical Pathways
02/15/2016
JCP Editors
New research on the genetics of different cancers has propelled the advance of new, novel treatment methods for diseases such as leukemia, lymphoma, and myeloma. The 57th ASH Annual Meeting and Exposition was a major...
New research on the genetics of different cancers has propelled the advance of new, novel treatment methods for diseases such as leukemia, lymphoma, and myeloma. The 57th ASH Annual Meeting and Exposition was a major...
New...
02/15/2016
Journal of Clinical Pathways
12/01/2015
JCP Editors
A new immunotherapy may help to improve outcomes of patients with metastatic bladder cancer, according to the results of a Phase II study. Bladder cancer is one of the most common and deadly forms of cancer for men...
A new immunotherapy may help to improve outcomes of patients with metastatic bladder cancer, according to the results of a Phase II study. Bladder cancer is one of the most common and deadly forms of cancer for men...
A new...
12/01/2015
Journal of Clinical Pathways